Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a US$767,800 purchase order for its FebriDx® rapid diagnostic test from US distribution partner PHASE Scientific, marking further progress in the product’s commercial rollout.
The order will be fulfilled progressively through October 2026, with revenue recognised as products are shipped.
It represents the first purchase order linked to the US$5 million prepayment Lumos received after FebriDx was granted a Clinical Laboratory Improvement Amendments, or CLIA, waiver by the US Food and Drug Administration in March 2026.
Order supports Year 1 commitment
The purchase order will contribute toward PHASE Scientific’s minimum Year 1 order commitment under its distribution agreement with Lumos.
Its value will be credited against the US$5 million prepayment, leaving the remaining balance available to support further orders.
Lumos said the timing of the order was significant as US healthcare providers prepare for the upcoming influenza season, when demand for rapid respiratory infection testing is expected to increase.
“We are encouraged by the continued momentum as we advance the commercialisation of FebriDx,” Lumos chief executive officer and managing director Doug Ward said.
“This order comes at an important time as US healthcare providers prepare for the upcoming flu season.
“We look forward to supporting the continued adoption of rapid, point-of-care acute respiratory infection testing across the US market.”
FebriDx targets respiratory infections
FebriDx is a rapid point-of-care diagnostic test designed to help healthcare professionals assess acute respiratory infections.
The FDA’s CLIA waiver allows the test to be used in a broader range of healthcare settings in the United States, supporting Lumos’ strategy to expand its commercial footprint in the world’s largest healthcare market.
The PHASE Scientific partnership provides Lumos with an established distribution channel as it works to increase adoption of FebriDx among US healthcare providers.
Next steps
Lumos will progressively ship the order through October and continue working with PHASE Scientific to secure further purchase orders against the remaining prepayment balance.
The company will also focus on supporting uptake ahead of the US flu season and building broader adoption of rapid point-of-care respiratory infection testing.
About Lumos Diagnostics
Lumos Diagnostics specialises in rapid point-of-care diagnostic technologies designed to help healthcare professionals diagnose and manage medical conditions more accurately.
The company provides customised assay development and manufacturing services, proprietary digital reader platforms and a portfolio of Lumos-branded tests targeting infectious and inflammatory diseases.